Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial

医学 握力 等长运动 安慰剂 物理疗法 手部力量 肌萎缩 肌生成抑制素 最佳步行速度 随机对照试验 物理医学与康复 内科学 骨骼肌 替代医学 病理
作者
Clemens Becker,Stephen R. Lord,Stephanie A. Studenski,Stuart J. Warden,Roger A. Fielding,Christopher Recknor,Marc C. Hochberg,Serge Ferrari,Hubert Blain,Ellen F. Binder,Yves Rolland,Serge Poiraudeau,Charles Benson,Stephen L. Myers,Leijun Hu,Qasim Ahmad,Kelli R Pacuch,Elisa V Gomez,Olivier Bénichou
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:3 (12): 948-957 被引量:361
标识
DOI:10.1016/s2213-8587(15)00298-3
摘要

Background Myostatin inhibits skeletal muscle growth. The humanised monoclonal antibody LY2495655 (LY) binds and neutralises myostatin. We aimed to test whether LY increases appendicular lean body mass (aLBM) and improves physical performance in older individuals who have had recent falls and low muscle strength and power. Methods In this proof-of-concept, randomised, placebo-controlled, double-blind, parallel, multicentre, phase 2 study, we recruited patients aged 75 years or older who had fallen in the past year from 21 investigator sites across Argentina, Australia, France, Germany, Sweden, and the USA. Eligible patients had low performance on hand grip strength and chair rise tests, tested with the procedure described by Guralnik and colleagues. Participants were stratified by country, age, hand grip strength, and performance on the chair rise test, and were randomly assigned (1:1) by a computer-generated random sequence to receive subcutaneous injections of placebo or 315 mg LY at weeks 0 (randomisation visit), 4, 8, 12, 16, and 20, followed by 16 weeks observation. The primary outcome was change in aLBM from baseline to 24 weeks. We measured physical performance as secondary outcomes (four-step stair climbing time, usual gait speed, and time to rise five times from a chair without arms, or with arms for participants unable to do it without arms) and exploratory outcomes (12-step stair climbing test, 6-min walking distance, fast gait speed, hand grip strength, and isometric leg extension strength). Efficacy analyses included all randomly assigned patients who received at least one dose and had a baseline and at least one subsequent measure. The primary analysis and all other tests of treatment effect (except physical performance tests) were done at a two-sided alpha level of 0·05. Tests of treatment effect on physical performance tests were done at a pre-specified two-sided alpha level of 0·1. This trial is registered with ClinicalTrials.gov, number NCT01604408. Findings Between June 19, 2012, and Dec 12, 2013, we screened 365 patients. 99 were randomly assigned to receive placebo and 102 to receive LY. Treatment was completed in 85 (86%) of patients given placebo and in 82 (80%) given LY. At 24 weeks, the least-squares mean change in aLBM was −0·123 kg (95% CI −0·287 to 0·040) in the placebo group and 0·303 kg (0·135 to 0·470) in the LY group, a difference of 0·43 kg (95% CI 0·192 to 0·660; p<0·0001). Stair climbing time (four-step and 12-step tests), chair rise with arms, and fast gait speed improved significantly from baseline to week 24 with differences between LY and placebo of respectively −0·46 s (p=0·093), −1·28 s (p=0·011), −4·15 s (p=0·054), and 0·05 m/s (p=0·088). No effect was detected for other performance-based measures. Injection site reactions were recorded in nine (9%) patients given placebo and in 31 (30%) patients given LY (p<0·0001), and were generally mild, and led to treatment discontinuation in two patients given LY. Interpretation Our findings show LY treatment increases lean mass and might improve functional measures of muscle power. Although additional studies are needed to confirm these results, our data suggest LY should be tested for its potential ability to reduce the risk of falls or physical dependency in older weak fallers. Funding Eli Lilly and Company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无私鹤轩发布了新的文献求助10
刚刚
刚刚
无私鹤轩发布了新的文献求助10
刚刚
carbonhan发布了新的文献求助10
刚刚
无私鹤轩发布了新的文献求助10
1秒前
1秒前
无私鹤轩发布了新的文献求助10
1秒前
无私鹤轩发布了新的文献求助10
1秒前
无私鹤轩发布了新的文献求助10
1秒前
超级安阳完成签到 ,获得积分10
2秒前
想看雪的人完成签到 ,获得积分10
2秒前
无私鹤轩发布了新的文献求助10
2秒前
无私鹤轩发布了新的文献求助10
2秒前
2秒前
菜菜完成签到 ,获得积分10
3秒前
酱酱完成签到 ,获得积分10
3秒前
3秒前
柚子发布了新的文献求助10
3秒前
4秒前
Xk发布了新的文献求助10
7秒前
小蘑菇的应助被kitten采纳,获得10
9秒前
yshog完成签到,获得积分10
10秒前
yuan完成签到,获得积分10
10秒前
istor发布了新的文献求助10
10秒前
10秒前
布式鹿炽完成签到,获得积分10
11秒前
12秒前
柚子完成签到,获得积分20
12秒前
Cyber_relic完成签到,获得积分10
12秒前
无私鹤轩发布了新的文献求助10
13秒前
无私鹤轩发布了新的文献求助10
13秒前
风吹麦浪发布了新的文献求助10
13秒前
无私鹤轩发布了新的文献求助10
14秒前
无私鹤轩发布了新的文献求助10
14秒前
无私鹤轩发布了新的文献求助10
14秒前
Spike完成签到,获得积分10
14秒前
无私鹤轩发布了新的文献求助10
15秒前
无私鹤轩发布了新的文献求助10
15秒前
15秒前
无私鹤轩发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191072
求助须知:如何正确求助?哪些是违规求助? 9578083
关于积分的说明 21856545
捐赠科研通 7790236
什么是DOI,文献DOI怎么找? 3436520
关于科研通互助平台的介绍 2560326
邀请新用户注册赠送积分活动 2483237